LONDON (Thomson Financial) - Biotech company Taihua Plc. reported a smaller
pretax profit as sales for the period fell 18 percent, hit by a ban on sale of
Chinese traditional medicines.
Taihua's sales and profits suffered as a result of a government-imposed ban
that came after a raft of fake-drug scandals rocked China in February 2008.
For the six months to June 30, pretax profit fell to 14.6 million yuan from
18.1 million as sales fell 11 percent to 29.8 million yuan.
TFN.newsdesk@thomson.com
ssa/slm
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|